Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne

@inproceedings{Lourbakos2017EvaluationOS,
  title={Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne},
  author={Afrodite Lourbakos and Nico Yau and Peter J de Bruijn and Monika Hiller and Karolina Kozaczynska and Rachel Jean-Baptiste and Mojgan Reza and Ron Wolterbeek and Za{\"i}da Koeks and Burcu Ayoglu and Dani{\"e}l de Klerk and Giles V. Campion and Irina T. Zaharieva and Vishna Devi Nadarajah and Peter Nilsson and Cristina Al-Khalili Szigyarto and Francesco Muntoni and Hanns Lochm{\"u}ller and Jan J G M Verschuuren and Nathalie M. Goemans and M{\'a}r H. Tulinius and Erik H. Niks and Sjef J. de Kimpe and Annemieke Aartsma-Rus and Peter A C 't Hoen and Pietro Spitali},
  booktitle={Scientific Reports},
  year={2017}
}
Duchenne Muscular Dystrophy (DMD) is a severe muscle disorder caused by lack of dystrophin. Predictive biomarkers able to anticipate response to the therapeutic treatments aiming at dystrophin re-expression are lacking. The objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomarker for Duchenne. Two natural history… CONTINUE READING